Abstract
Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (Choo et al., 1989; Saito et al., 1990). Infection with HCV is frequently associated with B-cell-related diseases, such as mixed cryoglobulinaemia and non-Hodgkin's lymphoma (Hausfater et al., 2000). A number of studies have suggested that HCV can replicate not only in hepatocytes, but also in lymphocytes (Ducoulombier et al., 2004; Karavattathayyil et al., 2000, Lerat et al., 1998), whereas the determinants of HCV tropism are still unknown. The development of HCV strain JFH-1, which generates infectious HCV in culture, has made an important contribution to the study of the HCV life cycle (Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005). The HCV life cycle is divided into several steps. After entry into the cell and uncoating, the HCV life cycle leads to translation, polyprotein processing, RNA replication, virion assembly, transport and release. The JFH-1 subgenomic replicon can replicate in non-hepatic cell lines, such as HeLa cells and 293 cells, suggesting that the host factors required for HCV replication are not hepatocyte-specific (Kato et al., 2005b). The SB strain of HCV (genotype 2b strain) was isolated from an HCV-infected non-Hodgkin's B-cell lymphoma and has been reported to infect B and T cells (Kondo et al., 2007; Sung et al., 2003). The virus titres of the SB strain in lymphocytes were, however, lower than those of JFH-1 in Huh-7 cells and the expression of HCV proteins was not confirmed (Kondo et al., 2007). It is unknown whether HCV JFH-1 can infect and replicate in lymphocytes. To gain more insight into the tissue tropism of HCV infection, we investigated the infection, replication, IRES-dependent translation and polyprotein processing of the JFH-1 strain in nine lymphocytic cell lines.
We first sought to determine whether HCV JFH-1 can infect lymphocytic cell lines. We chose nine lymphocytic cell lines derived from Burkitt's lymphoma, the EBV-immortalized human B cell line, lymphoblasts and acute T-cell leukaemia. C1R, IB4, Namalwa, P3HR1 and Raji cells were Epstein–Barr virus (EBV)-positive (Table 1). Infectious HCV was generated from HCV JFH-1 RNA in Huh-7 cells (Shirakura et al., 2007; Wakita et al., 2005) and the calculation of the 50 % tissue culture infectious dose (TCID50) was based on methods described previously (Lindenbach et al., 2005). These cell lines (1x105 cells per well of a six-well plate) were incubated with 2 ml inoculum (5x103 or 5x104 TCID50 ml–1) for 3 h, washed three times with PBS, and cultured in fresh medium. The culture medium was changed every 2 days. Cells were harvested at 0 (3 h post-infection [p.i.]), 4 and 8 day p.i. HCV core antigen within cells was quantified by immunoassay (Ortho HCV-core ELISA kit; Ortho-Clinical Diagnostics). As shown in Fig. 1(a), increasing the HCV titre of the inoculum resulted in a 7.2-fold increase in the levels of HCV core protein in Huh-7 cells at 3 h p.i. Increasing the HCV titre of the inoculum resulted in a 1.5- to 3.2-fold increase in the levels of the core protein in C1R, BL41, P3HR1 and Raji cells, suggesting that HCV can bind to these cell lines (Fig. 1a). In contrast, the levels of HCV core protein in IB4, Jurkat and Ramos cells at 3 h p.i. were below the detection limits and there were no significant differences in the levels of the core protein in Bjab cells and Namalwa cells, suggesting that HCV binding to these cells was very inefficient (Fig. 1a). Moreover, the levels of HCV core protein increased in Huh-7 cells but, in the case of all lymphocytic cell lines, including Raji cells, the core titre did not increase at day 4 and 8 p.i., suggesting that HCV JFH-1 does not infect and/or replicate efficiently in these lymphocytic cell lines (Fig. 1b).
Table 1. Summary of the virological characterization of HCV JFH-1 in lymphocytes
|
To assess the replication of JFH-1 in our lymphocytic cell lines, we utilized the HCV replicon system. To visualize the replicating cells, a reporter replicon plasmid was constructed as follows. The gene encoding green fluorescence protein (GFP) was fused to the neomycin resistance gene using an overlap PCR amplification technique and the fusion product was inserted into pSGR-JFH1. The resultant plasmid was pSGR-GFPneo-JFH1. This plasmid was linearized with XbaI and used as a template for in vitro transcription using an AmpliScribe T7 High Yield Transcription kit (Epicentre Biotechnologies). RNA was transfected with high transfection efficiency and low cytotoxicity using the Nucleofector system (Amaxa Biosystems) (Coughlin et al., 2004; Miyahara et al., 2005; Van De Parre et al., 2005). The transfection efficiencies ranged from 60 to 80 % after optimization of transfection conditions (Table 1). GFP expression was monitored periodically during the selection of HCV-replicon cells by G418 (Table 1). The GFP-expressing cells were detected at day 3 post-transfection (p.t.) in Huh-7, P3HR1, Raji, C1R and Namalwa cells. The rate of GFP expression in Huh-7 cells was more than 50 %. The rate of GFP-expression in lymphocytic cell lines was less than 1 %, despite the high transfection efficiencies. After 3 weeks of G418 selection, SGR-GFPneo-JFH1 replicon cells were established in Huh-7 cells, but not in lymphocytic cells. These data suggest that JFH-1 subgenomic replicon RNA cannot replicate in the lymphocytic cell lines.
To facilitate quantification of replication, we performed luciferase assays using subgenomic replicon RNA (SGR-JFH1/Luc) carrying firefly luciferase as a reporter. SGR-JFH1/Luc RNA was in vitro-transcribed using the linearized pSGR-JFH1/Luc (Kato et al., 2005a) as template DNA. Cells were harvested at 4, 24, 48 and 72 h p.t. and luciferase activities were assayed with luciferase assay reagent (Promega). Assays were performed at least in triplicate. There were significant differences in luciferase activities at 4 h p.t. among the cell lines, probably because there were differences in transfection efficiencies and the doubling time of the cell lines. Thus, the replication activity was expressed relative to the reporter activity determined 4 h p.t. for each cell line, which was set to 1 (Fig. 2a). HCV subgenomic replicon RNA efficiently replicated in Huh-7 cells (Fig. 2a). Replication-deficient subgenomic replicon RNA encoding a GDD to GND mutation in NS5B served as a negative control in Huh-7 cells. The luciferase activities of replication-deficient subgenomic replicon RNA in lymphocytic cell lines also decreased rapidly (data not shown). As shown in Fig. 2(a), the luciferase activities of HCV subgenomic replicon RNA in lymphocytic cell lines decreased rapidly, suggesting that HCV subgenomic replicon RNA did not replicate efficiently in lymphocytic cell lines. Thus, these two different replicon assays demonstrated that the HCV JFH-1 subgenomic replicon failed to replicate in our lymphocytic cell lines.
|
To determine which steps of the HCV life cycle are impaired, we further examined translation and polyprotein processing. At first, we assessed HCV IRES-dependent translational efficiencies in the lymphocytic cell lines. Cells were co-transfected with the subgenomic replicon RNA (SGR-JFH1/Luc) and a capped RNA encoding Renilla luciferase (cap-luc). Cap-luc RNA was in vitro-transcribed using a T7 mMessage mMachine kit (Ambion). The HCV IRES activities in IB4, Namalwa and P3HR1 cells were as high as in Huh-7 cells. The HCV IRES activities in Jurkat and Raji cells were about 50 % of those in Huh-7 cells, and the HCV IRES activities in Bjab, BL41 and Ramos cells were less than 25 % of those in Huh-7 cells. On the other hand, the HCV IRES activity in C1R cells was about twofold higher than in Huh-7 cells (Fig. 2b). Replication-deficient subgenomic replicon RNA encoding a GDD to GND mutation in NS5B showed a luciferase activity level similar to that of the wild-type, suggesting that the luciferase activity at 4 h after transfection reflected translational levels but not replication levels (data not shown). Our data indicate high HCV IRES activities in all cell lines, except in Bjab, BL41 and Ramos.
The HCV polyprotein is translated in subgenomic replicon cells in an encephalomyocarditis virus (EMCV) IRES-dependent manner. To rule out the possibility that the EMCV IRES-dependent translation is impaired in lymphocytic cell lines, we assessed the EMCV IRES-dependent translational efficiencies. We assayed EMCV IRES activity using EMCV IRES-driven luciferase RNA (EMC-luc) and Cap-luc RNA. The EMCV IRES activity was five- to tenfold higher in C1R, Namalwa, IB4 and P3HR1 than in Huh-7 cells (Fig. 2c). From these results, HCV IRES and EMCV IRES exhibited sufficient translational activity in C1R, Namalwa, P3HR1 and Raji cells, suggesting that IRES-dependent translation was not impaired in these lymphocytic cell lines.
To determine whether HCV polyprotein is properly processed in lymphocytes, we examined the processing of HCV non-structural (NS) proteins. The construct pSGR-JFH1/Luc expresses the polyprotein NS3-NS4A-NS4B-NS5A-NS5B. The HCV NS3/4A protease is responsible for proteolytic processing at each cleavage site. We used the eukaryotic transient-expression system based on a recombinant vaccinia virus carrying bacteriophage T7 RNA polymerase (T7vac) (Fuerst et al., 1989). To express the SGR-JFH1/Luc encoding HCV NS proteins, 5x106 cells were transfected with 5 µg pSGR-JFH1/Luc and infected with 2.5x109 p.f.u. T7vac, harvested at 24 h p.i., and analysed by Western blotting. Completely processed NS3, NS5A and NS5B proteins were detected in Bjab, Raji, IB4 and Namalwa cells as well as in pSGR-JFH1/Luc-transfected Huh-7 cells and HCV-JFH1-infected Huh-7 cells (Fig. 2c). The unprocessed polyprotein was not detected by immunoblotting in these lymphocytic cell lines (data not shown). These results suggest that the HCV polyprotein is efficiently processed in these lymphocytic cells.
In this study, we demonstrated that HCV JFH-1 failed to infect and replicate in nine lymphocytic cell lines. In contrast, HCV IRES-dependent translation and polyprotein processing by NS3/NS4A protease functioned properly in these cells. Moreover, subgenomic replicon RNA failed to replicate in these cell lines. Our data suggest that lymphocytic cell lines may lack some host factors required for infection and replication of HCV-JFH1.
Viral entry often requires sequential interactions between viral proteins and several cellular factors. Several molecules (CD81, Claudin-1, Scavenger receptor class B member IR, LDL-receptor and glycosaminoglycans) have been reported to be involved in HCV binding and entry (Barth et al., 2003; Evans et al., 2007; Pileri et al., 1998; Scarselli et al., 2002). Further investigation will be required to clarify HCV binding and entry into lymphocytic cell lines.
HCV IRES and EMCV IRES exhibited sufficient translational activities in C1R, IB4, P3HR1, Namalwa and Raji cells. All these cell lines are EBV-positive. EBV-encoded nuclear antigen (EBNA1) has been reported to support HCV replication (Sugawara et al., 1999). Two small EBV-encoded RNA species (EBERs) bind to the HCV IRES region (Wood et al., 2001). These findings raise the possibility that HCV IRES activities may be modified by the EBV genome.
HCV JFH-1 subgenomic replicon RNA could not replicate in all lymphocytes tested in this study. The HCV SB strain, however, has been reported to infect Raji, Daudi, Molt-4 and Jurkat cells (Kondo et al., 2007; Sung et al., 2003). Still unknown is how hepatotropism and lymphotropism of HCV are determined. The GB virus B (GBV-B) is most closely related to HCV and the GBV-B infection of tamarins has been proposed as a good surrogate model for chronic hepatitis C (Bukh et al., 2001; Jacob et al., 2004; Lanford et al., 2003; Martin et al., 2003). A recent report has shown that GBV can disseminate to not only liver but also a variety of extrahepatic tissues such as haematolymphoid and genital tissues in tamarins (Ishii et al., 2007). Viral RNA cloned from plasma and liver from the tamarins showed no sequence heterogeneity, suggesting that host factors determine the pleiotropism (Ishii et al., 2007). It remains unclear how host factors and/or viral factors determine the tissue tropism of HCV. Further studies will be required to clarify the molecular mechanisms of HCV tissue tropism.
References
Bukh, J., Apgar, C. L., Govindarajan, S. & Purcell, R. H. (2001). Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees. J Med Virol 65, 694–697.[CrossRef][Medline]
Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362.
Coughlin, C. M., Vance, B. A., Grupp, S. A. & Vonderheide, R. H. (2004). RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103, 2046–2054.
Ducoulombier, D., Roque-Afonso, A. M., Di Liberto, G., Penin, F., Kara, R., Richard, Y., Dussaix, E. & Feray, C. (2004). Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39, 817–825.[CrossRef][Medline]
Evans, M. J., von Hahn, T., Tscherne, D. M., Syder, A. J., Panis, M., Wolk, B., Hatziioannou, T., McKeating, J. A., Bieniasz, P. D. & Rice, C. M. (2007). Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801–805.[CrossRef][Medline]
Fuerst, T. R., Fernandez, M. P. & Moss, B. (1989). Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector. Proc Natl Acad Sci U S A 86, 2549–2553.
Hausfater, P., Rosenthal, E. & Cacoub, P. (2000). Lymphoproliferative diseases and hepatitis C virus infection. Ann Med Interne (Paris) 151, 53–57.[Medline]
Ishii, K., Iijima, S., Kimura, N., Lee, Y. J., Ageyama, N., Yagi, S., Yamaguchi, K., Maki, N., Mori, K. & other authors (2007). GBV-B as a pleiotropic virus: distribution of GBV-B in extrahepatic tissues in vivo. Microbes Infect 9, 515–521.[CrossRef][Medline]
Jacob, J. R., Lin, K. C., Tennant, B. C. & Mansfield, K. G. (2004). GB virus B infection of the common marmoset (Callithrix jacchus) and associated liver pathology. J Gen Virol 85, 2525–2533.
Karavattathayyil, S. J., Kalkeri, G., Liu, H. J., Gaglio, P., Garry, R. F., Krause, J. R. & Dash, S. (2000). Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma. Am J Clin Pathol 113, 391–398.
Kato, T., Date, T., Miyamoto, M., Sugiyama, M., Tanaka, Y., Orito, E., Ohno, T., Sugihara, K., Hasegawa, I. & other authors (2005a). Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 43, 5679–5684.
Kato, T., Date, T., Miyamoto, M., Zhao, Z., Mizokami, M. & Wakita, T. (2005b). Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. J Virol 79, 592–596.
Kondo, Y., Sung, V. M., Machida, K., Liu, M. & Lai, M. M. (2007). Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology 361, 161–173.[CrossRef][Medline]
Lanford, R. E., Chavez, D., Notvall, L. & Brasky, K. M. (2003). Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. Virology 311, 72–80.[CrossRef][Medline]
Lerat, H., Rumin, S., Habersetzer, F., Berby, F., Trabaud, M. A., Trepo, C. & Inchauspe, G. (1998). In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 91, 3841–3849.
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R. & other authors (2005). Complete replication of hepatitis C virus in cell culture. Science 309, 623–626.
Martin, A., Bodola, F., Sangar, D. V., Goettge, K., Popov, V., Rijnbrand, R., Lanford, R. E. & Lemon, S. M. (2003). Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA. Proc Natl Acad Sci U S A 100, 9962–9967.
Miyahara, Y., Naota, H., Wang, L., Hiasa, A., Goto, M., Watanabe, M., Kitano, S., Okumura, S., Takemitsu, T. & other authors (2005). Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 11, 5581–5589.
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A. J., Houghton, M., Rosa, D. & other authors (1998). Binding of hepatitis C virus to CD81. Science 282, 938–941.
Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, S., Watanabe, Y., Koi, S., Onji, M. & other authors (1990). Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87, 6547–6549.
Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R. M., Acali, S., Filocamo, G., Traboni, C., Nicosia, A., Cortese, R. & Vitelli, A. (2002). The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21, 5017–5025.[CrossRef][Medline]
Shirakura, M., Murakami, K., Ichimura, T., Suzuki, R., Shimoji, T., Fukuda, K., Abe, K., Sato, S., Fukasawa, M. & other authors (2007). E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein. J Virol 81, 1174–1185.
Sugawara, Y., Makuuchi, M., Kato, N., Shimotohno, K. & Takada, K. (1999). Enhancement of hepatitis C virus replication by Epstein–Barr virus-encoded nuclear antigen 1. EMBO J 18, 5755–5760.[CrossRef][Medline]
Sung, V. M., Shimodaira, S., Doughty, A. L., Picchio, G. R., Can, H., Yen, T. S., Lindsay, K. L., Levine, A. M. & Lai, M. M. (2003). Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 77, 2134–2146.
Van De Parre, T. J., Martinet, W., Schrijvers, D. M., Herman, A. G. & De Meyer, G. R. (2005). mRNA but not plasmid DNA is efficiently transfected in murine J774A.1 macrophages. Biochem Biophys Res Commun 327, 356–360.[CrossRef][Medline]
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H. G. & other authors (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791–796.[CrossRef][Medline]
Wood, J., Frederickson, R. M., Fields, S. & Patel, A. H. (2001). Hepatitis C virus 3'X region interacts with human ribosomal proteins. J Virol 75, 1348–1358.
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T. & Chisari, F. V. (2005). Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102, 9294–9299.
Received 25 November 2007; accepted 18 March 2008.